Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus Corporation (CERS) will have management participation in two upcoming investor conferences, the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13th and TD Cowen’s 44th Annual Health Care Conference on March 6th. The company will also have a live webcast of the TD Cowen presentation, with a replay available on their website after the event.
02/01/2024 - 08:30 AM
CONCORD, Calif. --(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s website after the event.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California , the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe , and in late-stage clinical development in the U.S. Also in the U.S. , the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201398941/en/
Jessica Hanover – Vice President, Corporate Affairs
Source: Cerus Corporation
When is Cerus Corporation (CERS) participating in the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference?
Cerus Corporation (CERS) is participating in the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th.
What time will Cerus Corporation (CERS) participate in TD Cowen’s 44th Annual Health Care Conference?
Cerus Corporation (CERS) will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
Will there be a webcast of the TD Cowen presentation by Cerus Corporation (CERS)?
Yes, there will be a live webcast of the TD Cowen presentation by Cerus Corporation (CERS), with a replay available on their website after the event.
CERS Rankings
#5035 Ranked by Stock Gains
CERS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Concord
About CERS
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
